MAY 06, 2016 01:46 PM PDT

Biomarker Predicts Childhood Cancer Relapse

WRITTEN BY: Xuan Pham
Lack of a protein indicates high risk of childhood cancer recurrence
Researchers say a protein biomarker could indicate whether a childhood cancer, neuroblastoma, will relapse. Absence of the marker, known as PML, was associated with tumor recurrence. The team says this piece of information could improve patient outcome, as therapies can be tailored according to a patient’s diagnostic result for the PML marker.
 
Neuroblastoma is a type of cancer that affects nerve cells in the sympathetic nervous system (PNS). This cancer is one of the most common forms of childhood cancer, affecting infants and young children. It is rarely found in children older than 10 years.
 
Children diagnosed with high-risk neuroblastoma, indicated by onset under 5 years of age and metastatic potential, are treated with intensive chemotherapy, surgery, radiation, and even bone marrow transplantation. In contrast, for low-risk neuroblastoma patients, doctors may opt to continuously monitor the tumor with or without surgical intervention. This method of “wait-and-see” has 90 percent prognosis rate for low-risk patients, but some deadly relapses can occur.
 
In testing neuroblastoma cell lines, the team at Brunel University London and University College London honed in on the PML protein, known formally as promyelocytic leukemia protein. They noted that PML is normally detected in the developing and adult PNS. However, PML expression was low or near absent in metastatic neuroblastoma tumors. The PML protein acts to suppress the development of blood vessels that feed the tumor cells, thus its absence is consistent with increased risk for tumor recurrence.
 
“In the low risk tumors, the absence of PML will be a very useful marker," said Arturo Sala, Professor at Brunel, and co-leader of the study. "What we can now say is that even some tumors classified as low risk, that would have previously gone untreated, if they show no expression of PML, they ought now to be classified as high risk.”
 
Indeed, the prognosis for low-risk neuroblastoma patients may even exceed 90 percent if these patients can be screened and treated promptly according to the presence or absence of PML. "It is an immediately applicable diagnostic tool," said Sala. "The cost is relatively small - it is just done by microscope inspection and could be used whenever a child is diagnosed by biopsy. If you save one child it is worthwhile."
 
In the next phase, the team has to validate their findings and confirm that PML levels can be predictive of neuroblastoma outcomes. Because the test would rely on a negative result – absence of PML – the team will need to find another biomarker to serve as a positive control. If successful, they will move to clinical trials to establish the effectiveness of this biomarker. 
 

Additional source: MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 19, 2019
Cancer
OCT 19, 2019
Combining Breast and Lung Cancer Drugs to Overcome Treatment Resistance
The efforts to overcome cancer’s ability to evolve and resist treatment take many forms and comprise a vital and active branch of contemporary cancer...
OCT 19, 2019
Cancer
OCT 19, 2019
New hope for metastatic cancer treatment
New research recently published in the journal iScience takes a deeper look into metastatic cancers, finding that a particular gene called mEAK-7 may play ...
OCT 19, 2019
Cell & Molecular Biology
OCT 19, 2019
Insight Into a DNA Damage Sensor That Orchestrates Repair
Simple cell functions like division or metabolism can lead to DNA damage, which can also occur because of normal exposure to the sun or noxious agents....
OCT 19, 2019
Cancer
OCT 19, 2019
Antibiotic use associated with bowel cancer
From 2000–2010, global consumption of antibiotics rose by 35% up to 70 billion doses each year. Although doctors are more cautious to prescribe antib...
OCT 19, 2019
Drug Discovery & Development
OCT 19, 2019
Comparison of Three Frontline Breast Cancer Drugs
Breast cancer affects 250,000 women in the U.S. annually. Those with most common form test positive for hormone receptors (HR+) and negative for the HER2 r...
OCT 19, 2019
Cancer
OCT 19, 2019
Gut fungi linked to pancreatic cancer
In a recent paper published in Nature paper, researchers from the New York University (NYU) School of Medicine in NYC report that gut fungi may be lin...
Loading Comments...